Update on ATM Facility
MedPal AI plc has successfully raised approximately £378,870 in gross proceeds through its At-The-Market equity issuance facility, issuing 6,200,000 new ordinary shares at an average price of 6.11p per share. These funds will bolster working capital for its online pharmaceutical subsidiary, MedPal Limited, enabling increased stock levels, product line expansion, and marketing for its pharmacy and clinic operations. To date, the company has raised a total of £877,095 via the ATM facility, which has a maximum capacity of £2 million. The new shares are expected to be admitted to trading on AIM around 22 January 2026, bringing the total issued ordinary shares to 433,599,640.
Select text to share a quote on X · sign in to keep highlights & notes in your MPAL notes
The Company has raised further gross proceeds of approximately £378,870 via the ATM facility through the issue of 6,200,000 new ordinary shares ("ATM Shares") at an average price of 6.11p per ATM Share. The proceeds of the ATM facility will provide additional working capital for MedPal AI's recently established online pharmaceutical subsidiary, MedPal Limited, to hold greater levels of stock, expand product lines and to undertake marketing campaigns to grow the pharmacy and clinic parts of the business, MedPal Pharmacy and Medpal.clinic.
Following this issue of shares, to date the Company has raised a total of £877,095 via the ATM facility, which enables the Company to raise up to £2 million subject to a minimum price per ATM Share of 5p. The announcement of 4 December 2025 can be viewed here irtools.co.uk/90/story/3ba161d5-8560-4c6d-8de9-a40e8eb9f1c1
Jason Drummond, Founder and CEO of MedPal AI, commented:
"We are delighted with the success of the ATM facility, which is performing exceptionally well, closing a further tranche at market price with no discount. This demonstrates strong investor confidence in MedPal AI's growth strategy. The funds raised will enable us to continue driving the business forward as we deliver month-on-month growth in both revenues and orders across our app, pharmacy and clinic operations."
Admission and Voting Rights
Application has been made for the 6,200,000 ATM Shares to be admitted to trading on AIM ("Admission"). Admission is expected to become effective and dealings in the ATM Shares are expected to commence on or around 22 January 2026.
Upon Admission, the Company's issued ordinary share capital will consist of 433,599,640 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, from Admission the total number of Ordinary Shares and voting rights in the Company will be 433,599,640. With effect from Admission, this figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Directors of the Company are responsible for the contents of this announcement.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.